BUSINESSFINANCIAL TIMES WORLD
Samsung Biologics buys Swiss peptide maker for $1.8bn
Samsung Biologics has acquired a Swiss peptide manufacturer for $1.8 billion. This acquisition exemplifies South Korean companies expanding abroad through acquisitions.
Related Signal
Adjacent reporting
- Samsung Biologics to acquire Switzerland's PolyPeptide Group in $1.8 billion all-cash deal
- UCB to acquire maker of antibody treatments for autoimmune diseases
- STAT+: Pharmalittle: We’re reading about a $10.6 billion GSK deal, an AstraZeneca obesity pill, and more
- Chiesi Agrees to Buy KalVista Pharmaceuticals for $1.9 Billion
- GSK just announced its biggest purchase in eight years to rev up cancer portfolio it had previously wound down